// App-Quantinova.ai

1435 : Class I/II Histone Deacetylase Inhibitors Are a Potential Therapeutic For Notch-1 Driven T Cell Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Michaela Waibel

Principal Investigators

  • Edwin D Hawkins

  • Kelly M Ramsbottom

  • Benjamin P Martin

  • Ricky W Johnstone

Medical Centers

  • Cancer Therapeutics Program, Peter MacCallum Cancer Centre, Melbourne, Australia

  • Cancer Research, Peter MacCallum Cancer Research, Melbourne, Australia

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Cluster of Differentiation 2AP

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

Drug/Treatment

  • Panobinostat

  • Interleukin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved